Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 70 clinical trials
featured
Apixaban for the Reduction of Thrombo-Embolism in patients with Device-Detected Sub- Clinical Atrial fibrillation (ARTESiA)

Apixaban for the Reduction of Thrombo-Embolism in patients with Device-Detected Sub- Clinical Atrial fibrillation (ARTESiA)

vascular disease
embolism
atrial fibrillation
apixaban
stroke
  • 316 views
  • 24 Nov, 2020
  • 1 location
AnticoaguLation ONE Year After Ablation of Atrial Fibrillation in Patients With Atrial Fibrillation (ALONE AF Study)

(apixaban) and no oral anticoagulation in patient with sinus rhythm one year after catheter ablation of AF.

  • 0 views
  • 24 Jan, 2021
HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID)

quality of life associated with COVID-19. The first two treatment arms are Apixaban and Atorvastatin, with further treatment arms to be added at the direction of the UK COVID-19 Therapeutic

  • 0 views
  • 02 Aug, 2021
  • 1 location
Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension

and TIPSS (transjugular intrahepatic portosystemic shunt) or liver transplantation for severe cases. The investigators hypothesize that anticoagulation using Apixaban in patients with INCPH

  • 0 views
  • 04 Mar, 2021
  • 1 location
Apixaban for Prevention of Post-angioplasty Thrombosis of Hemodialysis Vascular Access

atrial fibrillation. They also replaced oral and parenteral anticoagulants in the treatment and prevention of deep vein thrombosis. Among the 4 available NOACs today, only apixaban had received approval

  • 0 views
  • 25 Jan, 2021
  • 2 locations
Better Outcomes for Anticoagulation Treatment Through Observation of Atrial Rhythm

There is a need to determine actual compliance of direct oral anticoagulants and how to improve this to reduce risk of stroke in patients with atrial fibrillation. Mobile health tools have been implemented world-wide in various patient populations as means of reducing cardiovascular risk and improving disease management. Results of …

  • 4 views
  • 08 Apr, 2021
  • 1 location
A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects

This Phase 1 study is planned to establish the clinical safety and pharmacokinetics profile of multiple dose of LT3001 drug product and to investigate drug interactions of LT3001 with potential concomitant medications in healthy subjects.

  • 0 views
  • 28 Mar, 2021
  • 1 location
Apixaban for Extended Anticoagulation (APIDULCIS)

with Apixaban 2,5 mg x 2 for 18 months as extended treatment. Patients at low risk, with normal D-dimer test, will stop anticoagulation definitely.

apixaban
thrombosis
d-dimer
anticoagulation therapy
pulmonary embolism
  • 6 views
  • 27 Mar, 2021
  • 1 location
Apixaban for the Acute Treatment of Venous Thromboembolism in Children

To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.

heparin
vitamin k antagonist
apixaban
venous thromboembolism
anticoagulation therapy
  • 0 views
  • 10 Aug, 2021
  • 179 locations
API-CAT STUDY for APIxaban Cancer Associated Thrombosis

The main objective is to determine whether a low-dose regimen of apixaban (2.5 mg bid) is non inferior to a full-dose regimen of apixaban (5 mg bid) for the prevention of recurrent venous

  • 9 views
  • 05 Mar, 2021
  • 120 locations